Compare Kinder Morgan Inc (KMI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Kinder Morgan Inc trades at $32.49 (market cap $71.81B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Kinder Morgan Inc pays a 3.66% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| KMI | VRTX | |
|---|---|---|
Market Cap | $71.81B | $127.55B |
Volume | 16,921,908 | 1,487,944 |
Sector | Energy | Health |
52-Week High | $34.31 | $557.96 |
52-Week Low | $25.84 | $407.37 |
Typical Hold Time | 150 Days | 120 Days |
Enterprise Value | $103.86B | $121.68B |
Dividend Yield | 3.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.25, up 1.35% with a bullish technical outlook. The company reported strong earnings beats in recent quarters with Q2 2026 EPS of $0.37 beating expectations of $0.32. Revenue grew to $16.94B in 2025 with improving profit margins. Analyst consensus shows mixed sentiment with 47% buy ratings and a $37.20 price target, representing 15% upside potential. Recent news highlights the company's $6B-$7B growth pipeline and resilience amid energy market volatility.
KMI presents a compelling investment case with stable fee-based revenues, dividend yield of approximately 4%, and strong project backlog. However, risks include high debt levels ($29.66B long-term debt), exposure to energy market volatility, and competitive pressures. The stock offers income and growth potential but requires monitoring of debt management and energy sector dynamics.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
